Back to all webinars
Hot Topics in the Treatment of CLL
Clemens Wendtner, Talha Munir, and Alessandra Tedeschi look back on the year so far in CLL, reviewing developments from clinical trials as well as real-world and comparative studies before considering how data drive individual treatment decisions.
Speakers
Recent developments and future opportunities in the treatment of CLL
Fast-forward to:
cBTKi monotherapy
670e22ccfe90e24591c908eb
Fixed-duration therapy
670e22effe90e24591c97d2b
Continuous or fixed-duration therapy
670e243afe90e24591c9f2ff
cBTKi monotherapy and disease biology
670e2458fe90e24591ca673f
Fixed-duration therapy and disease biology
670e249ffe90e24591cadfc8
Safety outcomes with continuous vs. fixed-duration therapies
670e2604fe90e24591cb5852
MRD-guided therapy
670e261bfe90e24591cbcc95
Developmental agents and regimens in CLL
670e264cfe90e24591ccb519
Summary
670e2666fe90e24591cd295e
Beyond clinical trials: Real-world data and comparative analyses
Fast-forward to:
The role of real-world and comparative studies
670e26eafe90e24591cd9e2d
TN CLL: Zanubrutinib vs IV
670e2703fe90e24591ce1274
R/R CLL: ASCEND vs ALPINE
670e272afe90e24591ce86bc
BTKi efficacy in R/R CLL
670e2741fe90e24591cefb05
Zanubrutinib vs other BTKis in R/R CLL
670e27b6fe90e24591cf730e
Real-world BTKi treatment patterns and outcomes in CLL
670e2880fe90e24591d0e66e
Adverse events with BTKis
670e289dfe90e24591d15e79
Summary
670e28bafe90e24591d1d4ea
Making individualized treatment decisions in CLL: Case discussions
Fast-forward to:
Patient case 1
670e2926fe90e24591d25f29
Patient case 2
670e2937fe90e24591d2d59c
Summary & Q&A
Fast-forward to:
Interpreting results of a MAIC
670e2957fe90e24591d350e1
Using TP53 VAF cut-offs
670e2976fe90e24591d3c7df
Impact of therapy on infections and vaccinations
670e2992fe90e24591d43cbd
Venetoclax-ibrutinib
670e29a9fe90e24591d4b110